Respiratory syncytial virus (RSV) is a common virus that infects children and adults; however, children under the age of two tend to have more severe respiratory symptoms. Treatment is mainly supportive care, and most children's disease resolves without complications. Palivizumab for prevention of RSV is an option for high-risk infants and children and can reduce hospitalization and length of stay. This report contains market size and forecasts of Respiratory Syncytial Virus Treatment in Global, including the following market information: Global Respiratory Syncytial Virus Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions) Global top five companies in 2021 (%) The global Respiratory Syncytial Virus Treatment market was valued at US$ million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028. The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028. Oral Segment to Reach $ Million by 2028, with a % CAGR in next six years. The global key manufacturers of Respiratory Syncytial Virus Treatment include AstraZeneca, AbbVie, Pfizer, Zydus Pharmaceuticals, Merck and Bausch Health, etc. In 2021, the global top five players have a share approximately % in terms of revenue. MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Respiratory Syncytial Virus Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks. Total Market by Segment: Global Respiratory Syncytial Virus Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions) Global Respiratory Syncytial Virus Treatment Market Segment Percentages, by Type, 2021 (%) Oral Injection Global Respiratory Syncytial Virus Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions) Global Respiratory Syncytial Virus Treatment Market Segment Percentages, by Application, 2021 (%) Hospital Pharmacy Global Respiratory Syncytial Virus Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) Global Respiratory Syncytial Virus Treatment Market Segment Percentages, By Region and Country, 2021 (%) North America US Canada Mexico Europe Germany France U.K. Italy Russia Nordic Countries Benelux Rest of Europe Asia China Japan South Korea Southeast Asia India Rest of Asia South America Brazil Argentina Rest of South America Middle East & Africa Turkey Israel Saudi Arabia UAE Rest of Middle East & Africa Competitor Analysis The report also provides analysis of leading market participants including: Key companies Respiratory Syncytial Virus Treatment revenues in global market, 2017-2022 (estimated), ($ millions) Key companies Respiratory Syncytial Virus Treatment revenues share in global market, 2021 (%) Further, the report presents profiles of competitors in the market, key players include: AstraZeneca AbbVie Pfizer Zydus Pharmaceuticals Merck Bausch Health
1 Introduction to Research & Analysis Reports 1.1 Respiratory Syncytial Virus Treatment Market Definition 1.2 Market Segments 1.2.1 Market by Type 1.2.2 Market by Application 1.3 Global Respiratory Syncytial Virus Treatment Market Overview 1.4 Features & Benefits of This Report 1.5 Methodology & Sources of Information 1.5.1 Research Methodology 1
